Extract from BioStock’s analysis:
“Idogens present market cap or around SEK 100 million can be viewed as conservative, given that the company has received 42.5 million SEK in a new issue, the company was the only recipient of the contribution of SEK 27.6 million from Horizon 2020, and that Idogen is also one of the recipients of the 49 MSEK in Vinnova’s funding. All this in addition to the company’s already existing liquid funds.”
Read the entire analysis update here in Swedish: https://www.biostock.se/2017/09/analysuppdatering-idogen-avancerar-med-starkta-finanser-och-aggressiv-utvecklingsplan/
For additional information about Idogen, please contact:
Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
Idogen develops tolerogenic immune therapies which re-program the immune system. The term “tolerogenic” refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for severe diseases with a large medical need currently lacking cure – such as autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment.
The treatment method comprises cells from the patient’s blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction, without affecting the other immune function. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The company’s next therapeutic area will be a tolerogenic vaccine to counteract organ rejection in transplantation, primarily kidney transplantation. Idogen’s tolerogenic immune therapy is expected to reduce the need for immunosuppressive therapy and increase transplant survival, and thereby reduce the risk of cancer and serious infections. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit http://www.idogen.com